Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double Blind, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

NCT03439137 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.

NCT NCT03439137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03439137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double Blind, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Lead sponsor
Tanabe Pharma Corporation
Phase
Phase 3
Overall status
Completed
Start date
February 14, 2018
Completion date
July 16, 2019
Enrollment
323 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

anemia; hemodialysis dependent chronic kidney disease